Jefferies Financial Group Inc. Purchases Shares of 10,657 Masimo Co. (NASDAQ:MASI)

Jefferies Financial Group Inc. acquired a new stake in Masimo Co. (NASDAQ:MASI - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,657 shares of the medical equipment provider's stock, valued at approximately $1,762,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Envestnet Asset Management Inc. boosted its position in Masimo by 17.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 31,107 shares of the medical equipment provider's stock valued at $5,142,000 after purchasing an additional 4,579 shares during the period. Lecap Asset Management Ltd. purchased a new stake in Masimo in the 4th quarter worth about $1,607,000. Nisa Investment Advisors LLC boosted its holdings in shares of Masimo by 16,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider's stock worth $835,000 after purchasing an additional 5,022 shares during the period. Trust Point Inc. purchased a new position in shares of Masimo during the 4th quarter valued at $230,000. Finally, Barclays PLC grew its stake in Masimo by 152.6% in the third quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock valued at $5,329,000 after purchasing an additional 24,137 shares in the last quarter. 85.96% of the stock is owned by institutional investors.

Insider Buying and Selling at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. The trade was a 11.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,053 shares of company stock worth $6,998,565. Company insiders own 9.70% of the company's stock.

Masimo Price Performance

Shares of MASI traded up $0.23 during trading hours on Tuesday, hitting $155.36. The stock had a trading volume of 63,815 shares, compared to its average volume of 650,546. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The stock has a market capitalization of $8.42 billion, a price-to-earnings ratio of 106.91 and a beta of 1.23. The company's fifty day moving average is $159.81 and its two-hundred day moving average is $167.57. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.12. The firm had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Masimo's revenue was down 24.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.77 EPS. On average, analysts anticipate that Masimo Co. will post 4.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Piper Sandler reissued an "overweight" rating and set a $200.00 target price (down from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. BTIG Research set a $193.00 price target on shares of Masimo and gave the company a "buy" rating in a report on Wednesday, May 7th. Raymond James dropped their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company lowered their price objective on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $191.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.